UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (MARK ONE) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarter ended September 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-42106 RF ACQUISITION CORP II (Exact Name of Registrant as Specified in Its Charter) Cayman Islands N/A (State or other jurisdiction of ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________________________________________ FORM 10-Q ______________________________________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2025 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0 ...

Share Repurchase and Capital Management - The company repurchased 5.0 million shares for $48.1 million, with $97.3 million remaining under the share repurchase program[124] - The company repurchased approximately 11.1 million shares for $102.7 million during the nine months ended September 30, 2025, with a total repurchase amount of $195.2 million since the program's inception[193] - The company expects to fund its remaining 2025 capital spending program of $480.0 million to $520.0 million and decommissioning obligations of $100.0 million to $120.0 million through cash flows and available credit[191] Financial Performance - Total revenues for Q3 2025 were $450.1 million, a decrease of 11.6% from $509.3 million in Q3 2024[161] - Oil revenues decreased by $67.4 million (14.4%) to $400.2 million in Q3 2025 compared to $467.6 million in Q3 2024[161] - Natural gas revenues increased by $15.4 million (59.3%) to $41.3 million in Q3 2025 from $25.9 million in Q3 2024[161] - Operating cash flows increased by $120.8 million to $734.0 million for the nine months ended September 30, 2025, compared to $613.3 million in the same period of 2024[195] Production and Operational Metrics - Total production volume for Q3 2025 was 8.8 million Boe, a slight decrease of 1.4% from 8.9 million Boe in Q3 2024[161] - Daily oil production averaged 66.6 MBblpd in Q3 2025, down from 68.0 MBblpd in Q3 2024[161] - Production volumes decreased by 1.3 MBoepd to 95.2 MBoepd for the three months ended September 30, 2025, primarily due to well performance and natural production declines[163] - For the nine months ended September 30, 2025, production volumes increased by 6.0 MBoepd to 96.5 MBoepd, driven by production from assets acquired in the QuarterNorth Acquisition[164] Expenses and Impairments - Lease operating expenses for the three months ended September 30, 2025 decreased by approximately $29.6 million, or 18%, to $133.7 million compared to the same period in 2024[165] - Lease operating expenses for the nine months ended September 30, 2025 decreased by approximately $57.3 million, or 13%, to $398.5 million compared to the same period in 2024[166] - Depreciation, depletion, and amortization (DD&A) expense for the three months ended September 30, 2025 decreased by approximately $11.6 million, or 4%, to $262.6 million[167] - DD&A expense for the nine months ended September 30, 2025 increased by approximately $64.1 million, or 9%, to $813.1 million due to increased production volumes[168] - The company recorded a $60.2 million impairment of oil and natural gas properties for the three months ended September 30, 2025[171] Liquidity and Debt - As of September 30, 2025, the company's available liquidity was $989.4 million, consisting of cash and capacity under the Bank Credit Facility[188] - The company has a borrowing base of $700.0 million under its Bank Credit Facility, which is subject to regular redeterminations based on reserve estimates[188] - Interest expense for the three months ended September 30, 2025 decreased to $40.8 million from $46.3 million in the same period in 2024[172] Regulatory and Market Environment - The One Big Beautiful Bill Act mandates at least two offshore lease sales annually for the next 15 years, covering a minimum of 80 million acres[155] - A prolonged government shutdown could delay future federal lease sales and impact the company's operations[159] - The company anticipates volatility in oil, natural gas, and NGL prices, which could significantly impact revenues and profitability[137] - The company is navigating inflationary pressures that could increase capital expenditures and operating costs[139] Acquisitions and Investments - The company completed the Amberjack Acquisition, acquiring an additional 75.2% and 50.0% working interest in Mississippi Canyon blocks 108 and 110, respectively[131] - Cash used in investing activities decreased by $763.3 million, primarily due to $936.2 million paid for acquisitions related to the QuarterNorth Acquisition[196] Surety and Bonding Obligations - The company had surety bonds totaling approximately $1.5 billion primarily related to plugging and abandonment activities as of September 30, 2025[128] - The company anticipates a significant reduction in bonding requirements under the revised financial assurance rule[146] - The company has contractual obligations including a minimum spend of $90.0 million per year on plugging and abandonment activities starting January 1, 2026[201] - As of September 30, 2025, the company had outstanding performance bonds totaling $1.5 billion related to plugging and abandonment of wells in the U.S. Gulf of America[202] - The company also had outstanding letters of credit under its Bank Credit Facility totaling $43.3 million, which reduces available revolving credit commitments[202] Accounting and Reporting - There have been no changes to the company's critical accounting estimates from those disclosed in the 2024 Annual Report[203] - Information on recently adopted accounting standards impacting consolidated financial statements is referenced in the 2024 Annual Report[203] - The company has not experienced material changes in its exposures to certain market risks as disclosed in the 2024 Annual Report[204]

Financial Performance - Net product sales from NUPLAZID and DAYBUE totaled $787.5 million for the nine months ended September 30, 2025, a 12.8% increase from $698.2 million for the same period in 2024[83]. - Net product sales for the three months ended September 30, 2025, were $278.6 million, an increase from $250.4 million in the same period of 2024, representing an 11.3% growth[102]. - Net product sales of NUPLAZID increased to $177.5 million for the three months ended September 30, 2025, up from $159.2 million in 2024, reflecting an increase of 11.5%[103]. - Net product sales of DAYBUE rose to $101.1 million for the three months ended September 30, 2025, compared to $91.2 million in 2024, marking an increase of 10.9%[103]. - For the nine months ended September 30, 2025, net product sales were $787.5 million, up from $698.2 million in 2024, representing a growth of 12.8%[108]. Research and Development - Research and development expenses for the nine months ended September 30, 2025, were $244.0 million, compared to $202.5 million for the same period in 2024, reflecting a 20.5% increase[95]. - Total research and development expenses for the three months ended September 30, 2025, were $87.8 million, up from $66.6 million in the same period in 2024, marking a 31.7% increase[95]. - Research and development expenses increased to $87.8 million for the three months ended September 30, 2025, up from $66.6 million in 2024, a rise of 31.8%[106]. - The Phase 3 study of ACP-101 for Prader-Willi syndrome did not show statistically significant improvement, leading to the decision to discontinue further investigation[85]. - A Phase 2 study for ACP-204 targeting Alzheimer's disease psychosis was initiated in November 2023, with an additional study for Lewy Body Dementia planned[86]. - The company expects continued substantial research and development expenses as it advances its product candidates and fulfills post-marketing requirements[96]. Expenses - Selling, general and administrative expenses increased to $393.3 million for the nine months ended September 30, 2025, compared to $358.3 million in 2024, a rise of 9.8%[115]. - Selling, general and administrative expenses remained relatively flat at $133.4 million for the three months ended September 30, 2025, compared to $133.3 million in 2024[107]. - Selling, general and administrative expenses are influenced by market dynamics in the PDP and Rett syndrome markets[97]. Cash and Investments - Cash, cash equivalents, and investment securities totaled $847.0 million at September 30, 2025, an increase of $91.0 million from $756.0 million at December 31, 2024[125]. - Net cash provided by operating activities totaled $158.6 million for the nine months ended September 30, 2025, compared to $117.3 million for the same period in 2024, reflecting a 35.3% increase[125]. - Net cash provided by financing activities increased to $27.2 million for the nine months ended September 30, 2025, compared to $4.9 million for the same period in 2024, primarily due to an increase in proceeds from the exercise of employee stock options and awards[127]. - The company has not engaged in any off-balance sheet arrangements, thus avoiding material exposure to financing, liquidity, market, or credit risk[128]. - The company invests excess cash in investment-grade, interest-bearing securities, with a primary objective to preserve principal and liquidity[130]. - All investment securities have a credit rating of at least Aa3/AA- or P-1/A-1, ensuring high-quality investments[130]. - A hypothetical 10 percent change in interest rates as of September 30, 2025, would not have materially affected the fair value of the investment portfolio[130]. - The company does not expect anticipated changes in interest rates to have a material effect on its interest rate risk in future reporting periods[130]. Taxation - The company anticipates significant cash tax savings in 2025 due to changes in tax legislation affecting research cost expensing[99]. Overall Financial Position - The accumulated deficit as of September 30, 2025, was $2.1 billion, indicating substantial operating losses since inception[88].

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 _____________________________________________ FORM 10-Q _____________________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to ____________ Commission File N ...

Financial Performance - Total revenue for Q3 2025 was $363.8 million, a 16% increase from $312.7 million in Q3 2024[3] - Net income for Q3 2025 was $1.1 million, compared to a net loss of $6.0 million in the prior year, representing a 118% improvement[4] - Adjusted EBITDA increased by 31% to $40.2 million, with an Adjusted EBITDA margin of 11.1%[6] - For the full year 2025, the company expects revenue between $1.41 billion and $1.43 billion, with Adjusted EBITDA guidance raised to $146 million to $152 million[12] - Total revenue for the three months ended September 30, 2025, was $363.8 million, a 16.4% increase from $312.7 million in the same period of 2024[21] - Net income for the three months ended September 30, 2025, was $1.1 million, compared to a net loss of $6.0 million in the same period of 2024[21] - Adjusted EBITDA for the nine months ended September 30, 2025, was $108.9 million, a 25.2% increase from $87.0 million in the same period of 2024[26] Operational Metrics - The clinician base grew by 11% to 7,996 clinicians, with a net increase of 288 clinicians in Q3 2025[4] - Visit volumes increased by 17% to 2.3 million in Q3 2025[4] - Center Margin for Q3 2025 was $116.6 million, representing 32.0% of total revenue, a 16% increase year-over-year[5] - Center margin for the three months ended September 30, 2025, was $116.6 million, compared to $100.4 million in the same period of 2024[24] Cash Flow and Debt - Net cash provided by operations was $27.3 million in Q3 2025, contributing to a strong cash position of $203.9 million[4] - Free Cash Flow for Q3 2025 was positive at $17.0 million[4] - Cash flows from operating activities for the nine months ended September 30, 2025, were $88.6 million, compared to $44.9 million in the same period of 2024[23] - Cash and cash equivalents at the end of the period on September 30, 2025, were $203.9 million, up from $102.6 million at the end of September 2024[23] - The company reported a net increase in cash and cash equivalents of $49.3 million for the nine months ended September 30, 2025[23] - The company ended Q3 2025 with net long-term debt of $269.4 million[7] Expenses - Operating expenses for the three months ended September 30, 2025, totaled $356.4 million, up from $312.7 million in the same period of 2024[21] - General and administrative expenses for the three months ended September 30, 2025, were $95.6 million, an increase from $85.3 million in the same period of 2024[21] - Depreciation and amortization for the nine months ended September 30, 2025, was $41.3 million, down from $56.3 million in the same period of 2024[23]

Financial Performance - Total revenue for Q3 2025 reached $116,796,000, a 67% increase from $69,958,000 in Q3 2024[17] - Operating income for Q3 2025 was $35,561,000, compared to $20,842,000 in Q3 2024, reflecting a 70% increase[17] - Net income for Q3 2025 was $26,671,000, up from $15,446,000 in Q3 2024, representing a 73% increase[17] - Net income for the nine months ended September 30, 2025, was $90,439,000, compared to $53,155,000 for the same period in 2024, representing an increase of 70%[23] - Total revenue for the nine months ended September 30, 2025, reached $320.4 million, compared to $172.9 million in 2024, marking an increase of 85%[38] Assets and Equity - Total current assets increased to $329,454,000 as of September 30, 2025, from $257,619,000 at the end of 2024, a growth of 28%[15] - Total assets grew to $366,964,000 as of September 30, 2025, compared to $298,372,000 at the end of 2024, marking a 23% increase[15] - Total stockholders' equity increased to $155,270,000 as of September 30, 2025, up from $87,835,000 at the end of 2024, a growth of 77%[15] Cash Flow and Liquidity - Cash and cash equivalents increased to $104,147,000 as of September 30, 2025, from $73,185,000 at the end of 2024, a rise of 42%[15] - Net cash provided from operating activities for the nine months ended September 30, 2025, was $55,618,000, compared to $39,928,000 in 2024, an increase of 39%[23] - Cash, cash equivalents, and restricted cash at the end of the period on September 30, 2025, totaled $134,656,000, up from $88,343,000 in 2024, an increase of 52%[23] Credit Losses and Risk Management - Provision for credit losses for Q3 2025 was $32,177,000, significantly higher than $15,402,000 in Q3 2024, indicating increased risk management measures[17] - The company recognized a provision for credit losses of $32.2 million for Q3 2025, compared to $15.4 million in Q3 2024, representing a 109.7% increase[55] - The allowance for credit losses increased to $33.7 million as of September 30, 2025, compared to $18.6 million at the end of Q3 2024[55] Revenue Sources - Merchant and partner income totaled $26.0 million for Q3 2025, up from $21.9 million in Q3 2024, representing a 18.7% increase[40] - Transaction income from consumer fees increased significantly to $33.5 million in Q3 2025, compared to $14.5 million in Q3 2024, marking a 131% growth[41] - Subscription revenue for Q3 2025 was $24.3 million, compared to $22.9 million in Q3 2024, reflecting a 6.1% increase[44] Expenses - Marketing, advertising, and tradeshow expenses surged by 221.9% to $8.8 million for the three months ended September 30, 2025, compared to $2.7 million in 2024[115] - Personnel expenses increased by 6.7% to $14.3 million for the three months ended September 30, 2025, compared to $13.4 million in 2024[110] - Third-party technology and data expenses rose by 55.2% to $3.7 million for the three months ended September 30, 2025, compared to $2.4 million in 2024[114] Stock and Shareholder Actions - The company performed a 6-for-1 stock split effective March 28, 2025, impacting share and per share amounts retroactively[15] - The Board of Directors authorized a stock repurchase program of up to $50 million, effective from April 7, 2025, to April 7, 2026[158] - During the three months ended September 30, 2025, the company purchased 47,089 shares at an average price of $84.24 to cover tax obligations[157] Legal and Regulatory Matters - The company filed a lawsuit against Shopify for antitrust violations, seeking damages that could be tripled under applicable laws[153] - The company does not believe that the outcome of ongoing legal matters will have a material adverse effect on its financial position[154] - The company is currently assessing the impact of the One Big Beautiful Bill Act enacted on July 4, 2025, which includes significant tax provisions[37] Taxation - Income tax expense for the nine months ended September 30, 2025, was $20,871,000, compared to a benefit of $(13,567,000) in 2024, reflecting a significant change[122] - The effective income tax rate for the three months ended September 30, 2025, was 15.7%, up from 12.3% in 2024, while for the nine months it was 18.8% compared to (34.3%) in 2024[122] Consumer Metrics - Active Consumers increased to 2.971 million as of September 30, 2025, representing a 9.0% growth from 2.725 million at the end of 2024[87] - Monthly On-Demand Users and Subscribers (MODS) rose to 784,000, an 11.0% increase from 707,000 in December 2024[87] Financial Controls and Compliance - As of September 30, 2025, the company's disclosure controls and procedures were deemed effective at a reasonable assurance level by the CEO and CFO[149] - No changes in internal control over financial reporting occurred during the nine months ended September 30, 2025, that materially affected internal controls[150] - The financial statements fairly present the financial condition and results of operations of Sezzle Inc. for the quarter ended September 30, 2025[172]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___ to ___ Commission file number 001-40653 Duolingo, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorpor ...

Financial Performance - Q3 2025 net sales were $466.5 million, a 4% increase from $448.0 million in Q3 2024, driven by pricing adjustments and foreign currency translation [4]. - Gross profit for Q3 2025 was $70.9 million, representing a gross margin of 15.2%, up from $58.8 million and 13.1% in Q3 2024 [5]. - Adjusted EBITDA for Q3 2025 increased to $30 million, compared to $20.5 million in the same period last year [16]. - Agricultural segment net sales rose by 7.6% to $188.7 million, with gross profit increasing by 50.9% to $25.2 million [10]. - Earthmoving/construction segment net sales grew by 6.6% to $145.4 million, with gross profit up 30.1% to $15.2 million [12]. - Consumer segment net sales decreased by 2.8% to $132.4 million, but gross profit remained stable at $30.5 million [14]. - Net sales for Q3 2025 were $466.5 million, a 4% increase from $448.0 million in Q3 2024 [27]. - Gross profit for Q3 2025 was $70.9 million, up 20.5% from $58.8 million in Q3 2024 [27]. - The net loss attributable to Titan for the three months ended September 30, 2025, was $(2,262,000), compared to $(18,249,000) for the same period in 2024 [38]. - Adjusted net income attributable to Titan for the nine months ended September 30, 2025, was $1,784,000, compared to $12,254,000 in 2024 [38]. Cash Flow and Debt - Free cash flow for Q3 2025 was $30 million, contributing to a reduction in net debt [3]. - The company expects Q4 2025 sales to be between $385 million and $410 million, with Adjusted EBITDA around $10 million [3]. - Total cash and cash equivalents at the end of Q3 2025 were $205.4 million, compared to $196.0 million at the end of 2024 [18]. - Net debt at September 30, 2025, was $372.9 million, slightly up from $369.5 million at the end of 2024 [18]. - Operating cash flow for the nine months ended September 30, 2025, was $17.2 million, down from $132.8 million in the same period of 2024 [31]. - Total liabilities increased to $1.18 billion as of September 30, 2025, from $1.09 billion at the end of 2024 [29]. - Interest expense for the nine months ended September 30, 2025, was $28.9 million, compared to $27.1 million for the same period in 2024 [27]. - Free cash flow for the three months ended September 30, 2025, was $29,889,000, down from $41,786,000 in 2024 [41]. - Total debt as of September 30, 2025, was $578,325,000, an increase from $565,445,000 as of December 31, 2024 [41]. Assets and Liabilities - Total assets as of September 30, 2025, were $1.75 billion, an increase from $1.58 billion at the end of 2024 [29]. - Cash and cash equivalents at the end of Q3 2025 were $205.4 million, compared to $195.9 million at the end of 2024 [29]. - Net debt as of September 30, 2025, was $372,944,000, compared to $369,471,000 as of December 31, 2024 [41]. Research and Development - Research and development expenses increased to $4.6 million in Q3 2025 from $4.2 million in Q3 2024, reflecting a focus on innovation [27]. Foreign Exchange and Other Losses - The company reported a foreign exchange loss of $6.4 million for the nine months ended September 30, 2025, compared to a loss of $2.3 million in the same period of 2024 [27]. Regional Performance - The company experienced a 21.9% increase in net sales in Latin America for the three months ended September 30, 2025, compared to the same period in 2024 [40].

Financial Performance - Net sales for Q3 2025 were $466,466,000, an increase of 4.3% compared to $447,985,000 in Q3 2024[8] - Gross profit for Q3 2025 was $70,871,000, up from $58,805,000 in Q3 2024, representing a 20.5% increase[8] - Net loss for Q3 2025 was $2,459,000, a significant improvement from a net loss of $18,199,000 in Q3 2024[9] - Comprehensive loss for Q3 2025 was $3,244,000, an improvement from a comprehensive loss of $5,466,000 in Q3 2024[9] - For the nine months ended September 30, 2025, Titan International, Inc. experienced a net loss of $6.041 million, compared to a net loss of $4.803 million for the same period in 2024[16] - The company recorded a net loss attributable to Titan of $(2,262) thousand for the three months ended September 30, 2025, compared to a net loss of $(18,249) thousand for the same period in 2024[83] - For the nine months ended September 30, 2025, net loss was $6.0 million compared to a net loss of $4.8 million in the same period of 2024, with basic and diluted loss per share increasing from $(0.10) to $(0.12)[148] Revenue and Sales - For the nine months ended September 30, 2025, Titan's total net sales reached $1,418,004,000, a decrease from $1,462,364,000 in the same period of 2024, representing a decline of about 3.0%[92] - Net sales for Q3 2025 were $466.5 million, a 4.1% increase from $448.0 million in Q3 2024, driven by pricing adjustments and foreign currency translation contributing approximately 1.2% to growth[124] - Agricultural segment net sales for the three months ended September 30, 2025, were $188.7 million, a 7.6% increase from $175.4 million in 2024, driven by higher sales volumes in the Americas[151] - Earthmoving/construction segment net sales for the three months ended September 30, 2025, were $145.4 million, a 6.6% increase from $136.3 million in 2024, primarily due to higher sales volumes in the Americas[158] - Consumer segment net sales for the three months ended September 30, 2025, were $132.4 million, a 2.8% decrease from $136.2 million in 2024, attributed to lower sales volumes in the Americas[165] Expenses and Costs - Research and development expenses increased to $4,550,000 in Q3 2025 from $4,199,000 in Q3 2024, reflecting a 8.4% rise[8] - Selling, general and administrative expenses for Q3 2025 were $53.1 million, or 11.4% of net sales, up from $49.5 million, or 11.1% of net sales, in Q3 2024, driven by inflationary cost impacts[128] - Interest expense for the nine months ended September 30, 2025, was $28,935,000, compared to $27,103,000 in the same period of 2024, showing an increase of about 6.8%[92] - The total depreciation and amortization expense for the three months ended September 30, 2025, was $16,794,000, up from $12,636,000 in the same period of 2024, reflecting an increase of about 32.5%[96] Assets and Liabilities - Total assets as of September 30, 2025, were $1,750,387,000, compared to $1,584,953,000 at the end of 2024, marking an increase of 10.4%[12] - Total liabilities rose to $1,175,958,000 as of September 30, 2025, compared to $1,091,297,000 at the end of 2024, indicating an increase of 7.7%[12] - Cash and cash equivalents increased to $205,381,000 as of September 30, 2025, up from $195,974,000 at the end of 2024[12] - Accounts receivable increased to $291.3 million as of September 30, 2025, compared to $214.9 million as of December 31, 2024[42] - Total inventories rose to $465.9 million as of September 30, 2025, up from $437.2 million as of December 31, 2024[44] Equity and Capital - Titan's total equity increased to $574,429,000 as of September 30, 2025, up from $493,656,000 at the end of 2024, reflecting a growth of 16.4%[12] - The company authorized a share repurchase program of up to $50 million, with $1 million remaining available for future repurchases as of September 30, 2025[27] - Long-term debt totaled $556,770,000 as of September 30, 2025, with a principal balance of $580,515,000 and unamortized debt issuance costs of $2,190,000[54] Cash Flow and Investments - Titan International, Inc. had net cash provided by operating activities of $17.243 million for the nine months ended September 30, 2025, significantly lower than $132.751 million in 2024[16] - Cash flows provided by operating activities were $17.2 million for the nine months ended September 30, 2025, a decrease of $115.5 million compared to the same period in 2024, mainly due to increased investment in working capital[177] - Net cash outflow from investing activities was $36.4 million for the nine months ended September 30, 2025, significantly lower than the $189.0 million outflow in 2024, primarily due to the absence of the Titan Specialty acquisition costs[180] Market and Operational Risks - Titan's financial performance is subject to risks such as geopolitical uncertainties and changes in domestic and international laws[105] - The company faces substantial uncertainties related to newly imposed tariffs, increased competition, and potential reductions in customer demand[206] - Titan is exposed to market risks, including changes in foreign currency exchange rates and interest rates, and commodity price fluctuations[198] Strategic Initiatives - The company plans to consider and pursue acquisition opportunities, which could significantly impact its financial results[106] - The company expects full-year capital expenditures to be between $50 million and $55 million, aimed at enhancing existing facilities and supporting new product development[194]